Delphic Diagnostics, a provider of specialist diagnostics for HIV and hepatitis since 2001, is pleased to announce the appointment of Alun Williams as Chief Executive. He succeeds Tim Leaver who will become a Non-Executive Director.
Alun brings to Delphic his experience of working at the highest levels of the healthcare sector. His background includes pharmaceuticals, clinical trials and medical devices. He has successfully developed and executed business and sales strategies in several companies, including supporting the flotation of QinetiQ plc.
Alun Williams said on his appointment: “I am delighted to be joining Delphic at this exciting time in its development. The company is uniquely positioned to supply the emergent market for biomarkers and companion diagnostics as the pharmaceutical industry moves rapidly towards the development of personalised medicine. I look forward to the challenge of turning Delphic into a pivotal provider of diagnostic services to CROs and the pharmaceutical industry.”
Dr Kevin Bryett, Chair of Delphic, said: “We are all very grateful to Tim Leaver for the solid foundation he has built for Delphic. I am delighted that we will retain his experience as a Non-Executive Director of the company. Alun Williams brings to Delphic broad experience of high level appointments in the global healthcare sector and I am confident that he will now take Delphic to the next level.”
Delphic has just completed an £850K fund-raising from existing investors MMC Ventures and The Capital Fund to support the transition of the company from its position as an established provider of specialist diagnostic services in HIV and hepatitis into a sector leader able to address the growing market for adaptive trials and personalised medicine across a range of therapy areas.
Delphic’s investors include MMC Ventures Ltd, The Capital Fund and Ulive Enterprises (the University of Liverpool’s IP commercialisation company).
Jon Coker of MMC, which led the investment, commented: “Tim Leaver has built the company from its inception and has managed it through the latest fund-raising round and the recent acquisition of iQur’s diagnostics business. With the arrival of Alun Williams, we are confident that Delphic will complete its evolution into a world-leading diagnostics company.”
